Cell line · CVCL_8054
624-mel
Cancer cell line, Homo sapiens. Melanoma. 38 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. 624-mel. Cell lines, record CVCL_8054. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_8054
On this page
Cell line
As Cellosaurus gives it.
- Name
- 624-mel
- Accession
- CVCL_8054
- RRID
- RRID:CVCL_8054
- Synonyms
- 624-MEL, 624 MEL, 624 Mel, 624 mel, 624mel, 624MEL, 624, Mel-624, Mel624, MEL624
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- Age unspecified
- Category
- Cancer cell line
- Diseases
- Melanoma (NCIt C3224)
- Derived from
- Not specified (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers38
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ImmTACs overcome cytotoxic T cell suppression. | Immunother Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineering editopes through programmable RNA editing toward tumor neoantigen generation. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MITF maintains genome stability in nonmelanocyte lineages. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. | Oncoimmunology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhanced IFNy response in dedifferentiated melanoma cells is due to chromatin remodeling as revealed by ATAC-seq. | Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD-L1 in melanoma. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 38
See all 38 papersRelatives7
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | 624-mel/A31 | CVCL_A1DV | Cell lines | |
| Derived from it | 624.28 Mel | CVCL_C586 | Cell lines | |
| Derived from it | 624.38 Mel | CVCL_C588 | Cell lines | |
| Derived from it | Mel501A | CVCL_0V14 | Cell lines | |
| Derived from it | Mel624-CMV-hNIS-Neo | CVCL_RA30 | Cell lines | |
| Derived from it | Mel624-CMV-hNIS-Neo/eGFP-Puro | CVCL_RA31 | Cell lines | |
| Derived from it | Mel624-hNIS-Neo | CVCL_RA32 | Cell lines |
Cell banks0
None in this release.
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8054
GET https://conductscience.org/api/cell-lines/v1/CVCL_8054/papers?page=2